title: Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients.
abstract: BACKGROUND
  Cervical total disk replacement (TDR) is intended to address pain and preserve motion between vertebral bodies in patients with symptomatic cervical disk disease. Two-year follow-up for the ProDisc-C (Synthes USA Products, LLC, West Chester, Pennsylvania) TDR clinical trial showed non-inferiority versus anterior cervical discectomy and fusion (ACDF), showing superiority in many clinical outcomes. We present the 4-year interim follow-up results.
  
  
  METHODS
  Patients were randomized (1:1) to ProDisc-C (PDC-R) or ACDF. Patients were assessed preoperatively, and postoperatively at 6 weeks and 3, 6, 12, 18, 24, 36, and 48 months. After the randomized portion, continued access (CA) patients also underwent ProDisc-C implantation, with follow-up visits up to 24 months. Evaluations included Neck Disability Index (NDI), Visual Analog Scale (VAS) for pain/satisfaction, and radiographic and physical/neurologic examinations.
  
  
  RESULTS
  Randomized patients (103 PDC-R and 106 ACDF) and 136 CA patients were treated at 13 sites. VAS pain and NDI score improvements from baseline were significant for all patients (P < .0001) but did not differ among groups. VAS satisfaction was higher at all time points for PDC-R versus ACDF patients (P = .0499 at 48 months). The percentage of patients who responded yes to surgery again was 85.6% at 24 months and 88.9% at 48 months in the PDC-R group, 80.9% at 24 months and 81.0% at 48 months in the ACDF group, and 86.3% at 24 months in the CA group. Five PDC-R patients (48 months) and no CA patients (24 months) had index-level bridging bone. By 48 months, approximately 4-fold more ACDF patients required secondary surgery (3 of 103 PDC-R patients [2.9%] vs 12 of 106 ACDF patients [11.3%], P = .0292). Of these, 6 ACDF patients (5.6%) required procedures at adjacent levels. Three CA patients required secondary procedures (24 months).
  
  
  CONCLUSIONS
  Our 4-year data support that ProDisc-C TDR and ACDF are viable surgical options for symptomatic cervical disk disease. Although ACDF patients may be at higher risk for additional surgical intervention, patients in both groups show good clinical results at longer-term follow-up.
authors: The Spine Center at Cedars-Sinai Medical Center, Los Angeles, CA.
authors: Rick B
authors: RB
authors: Delamarter
authors: OrthoCarolina, PA, OrthoCarolina Spine Center, Charlotte, NC.
authors: Daniel
authors: D
authors: Murrey
authors: Center for Spinal Disorders, Thornton, CO.
authors: Michael E
authors: ME
authors: Janssen
authors: New York University/Hospital for Joint Diseases, New York, NY.
authors: Jeffrey A
authors: JA
authors: Goldstein
authors: Texas Back Institute, Plano, TX.
authors: Jack
authors: J
authors: Zigler
authors: Department of Orthopaedic Surgery, University of California San Francisco, San Francisco, CA.
authors: Bobby K-B
authors: BK
authors: Tay
authors: OrthoCarolina, PA, OrthoCarolina Spine Center, Charlotte, NC.
authors: Bruce
authors: B
authors: Darden
keywords: Cervical arthroplasty; Symptomatic cervical disc disease; Total disc replacement